Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384663306> ?p ?o ?g. }
- W4384663306 endingPage "1044" @default.
- W4384663306 startingPage "1029" @default.
- W4384663306 abstract "Aim: We pooled patient-level data from three randomized controlled studies to evaluate the combination of pembrolizumab plus chemotherapy in patients with untreated advanced/metastatic non-small-cell lung cancer (NSCLC) and programmed cell death ligand 1 (PD-L1) tumor proportion score <1% in East Asia. Methods: The analysis included 107 patients from China, Japan, Korea, Thailand and Taiwan (pembrolizumab plus chemotherapy, n = 56; chemotherapy alone, n = 51). Results: For pembrolizumab plus chemotherapy versus chemotherapy alone, median overall survival was 21.3 versus 12.6 months (HR, 0.55 [95% CI: 0.35-0.87]) and median progression-free survival was 8.4 versus 6.0 months (HR, 0.64 [95% CI: 0.43-0.96]). Conclusion: The analysis supports the use of pembrolizumab in combination with platinum-based chemotherapy for East Asian patients with PD-L1-negative, advanced NSCLC.This analysis evaluated outcomes for East Asian patients with a type of advanced lung cancer which does not express a protein called programmed cell death ligand 1 (PD-L1). The patients received either an immunotherapy, called pembrolizumab, in combination with chemotherapy or chemotherapy alone. Overall survival (how long people live) and progression-free survival (how long people live without their disease getting worse) were longer for patients who received treatment with pembrolizumab plus chemotherapy versus those who received chemotherapy alone. Side effects among East Asian patients were similar to those previously described for a global patient population. These results support the use of pembrolizumab in combination with chemotherapy for East Asian patients with lung cancer that does not express PD-L1. Clinical Trial Registration: NCT02039674; NCT02578680; NCT03950674; NCT02775435; NCT03875092 (ClinicalTrials.gov)." @default.
- W4384663306 created "2023-07-20" @default.
- W4384663306 creator A5005546219 @default.
- W4384663306 creator A5007542358 @default.
- W4384663306 creator A5009971196 @default.
- W4384663306 creator A5023128001 @default.
- W4384663306 creator A5032326710 @default.
- W4384663306 creator A5048411184 @default.
- W4384663306 creator A5052132950 @default.
- W4384663306 creator A5055012172 @default.
- W4384663306 creator A5055074037 @default.
- W4384663306 creator A5055470683 @default.
- W4384663306 creator A5057704753 @default.
- W4384663306 creator A5062627395 @default.
- W4384663306 creator A5063817865 @default.
- W4384663306 creator A5066716873 @default.
- W4384663306 creator A5067152089 @default.
- W4384663306 creator A5067509137 @default.
- W4384663306 creator A5068743826 @default.
- W4384663306 creator A5072724155 @default.
- W4384663306 creator A5083209907 @default.
- W4384663306 creator A5086270619 @default.
- W4384663306 date "2023-09-01" @default.
- W4384663306 modified "2023-10-17" @default.
- W4384663306 title "Pembrolizumab plus chemotherapy for advanced non–small-cell lung cancer without tumor PD-L1 expression in Asia" @default.
- W4384663306 cites W2027224122 @default.
- W4384663306 cites W2037418758 @default.
- W4384663306 cites W2115330744 @default.
- W4384663306 cites W2145835533 @default.
- W4384663306 cites W2525700806 @default.
- W4384663306 cites W2527905628 @default.
- W4384663306 cites W2529904548 @default.
- W4384663306 cites W2567068937 @default.
- W4384663306 cites W2754947201 @default.
- W4384663306 cites W2796582438 @default.
- W4384663306 cites W2888059202 @default.
- W4384663306 cites W2892640821 @default.
- W4384663306 cites W2912044537 @default.
- W4384663306 cites W2921046410 @default.
- W4384663306 cites W2925446385 @default.
- W4384663306 cites W2949244813 @default.
- W4384663306 cites W2976744492 @default.
- W4384663306 cites W2979076666 @default.
- W4384663306 cites W2997233435 @default.
- W4384663306 cites W3009099064 @default.
- W4384663306 cites W3037506839 @default.
- W4384663306 cites W3037990514 @default.
- W4384663306 cites W3086245137 @default.
- W4384663306 cites W3093317346 @default.
- W4384663306 cites W3111665711 @default.
- W4384663306 cites W3134553072 @default.
- W4384663306 cites W3138328208 @default.
- W4384663306 cites W3139265240 @default.
- W4384663306 cites W3144903047 @default.
- W4384663306 cites W3154805493 @default.
- W4384663306 cites W3164672296 @default.
- W4384663306 cites W3164993995 @default.
- W4384663306 cites W3165007730 @default.
- W4384663306 cites W3194403670 @default.
- W4384663306 cites W3207786785 @default.
- W4384663306 cites W4205759188 @default.
- W4384663306 cites W4280533169 @default.
- W4384663306 cites W4303488453 @default.
- W4384663306 doi "https://doi.org/10.2217/imt-2023-0043" @default.
- W4384663306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37465924" @default.
- W4384663306 hasPublicationYear "2023" @default.
- W4384663306 type Work @default.
- W4384663306 citedByCount "0" @default.
- W4384663306 crossrefType "journal-article" @default.
- W4384663306 hasAuthorship W4384663306A5005546219 @default.
- W4384663306 hasAuthorship W4384663306A5007542358 @default.
- W4384663306 hasAuthorship W4384663306A5009971196 @default.
- W4384663306 hasAuthorship W4384663306A5023128001 @default.
- W4384663306 hasAuthorship W4384663306A5032326710 @default.
- W4384663306 hasAuthorship W4384663306A5048411184 @default.
- W4384663306 hasAuthorship W4384663306A5052132950 @default.
- W4384663306 hasAuthorship W4384663306A5055012172 @default.
- W4384663306 hasAuthorship W4384663306A5055074037 @default.
- W4384663306 hasAuthorship W4384663306A5055470683 @default.
- W4384663306 hasAuthorship W4384663306A5057704753 @default.
- W4384663306 hasAuthorship W4384663306A5062627395 @default.
- W4384663306 hasAuthorship W4384663306A5063817865 @default.
- W4384663306 hasAuthorship W4384663306A5066716873 @default.
- W4384663306 hasAuthorship W4384663306A5067152089 @default.
- W4384663306 hasAuthorship W4384663306A5067509137 @default.
- W4384663306 hasAuthorship W4384663306A5068743826 @default.
- W4384663306 hasAuthorship W4384663306A5072724155 @default.
- W4384663306 hasAuthorship W4384663306A5083209907 @default.
- W4384663306 hasAuthorship W4384663306A5086270619 @default.
- W4384663306 hasBestOaLocation W43846633061 @default.
- W4384663306 hasConcept C121608353 @default.
- W4384663306 hasConcept C126322002 @default.
- W4384663306 hasConcept C143998085 @default.
- W4384663306 hasConcept C2776256026 @default.
- W4384663306 hasConcept C2776694085 @default.
- W4384663306 hasConcept C2777701055 @default.
- W4384663306 hasConcept C2780057760 @default.
- W4384663306 hasConcept C71924100 @default.